Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin for COVID-19 in Diabetic Patients
NCT04365517Phase 3Unknown
- Sponsor
- University of Milan
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sitagliptin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Milan. Primary endpoints: Time for clinical improvement at 1 month, Clinical parameter of acute lung disease at 1 month and 1 more. Status: unknown.
02
Drugs
sitagliptin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04365517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365517.